- Home
- BAX vs GMAB Comparison
BAX vs GMAB Comparison
Compare BAX & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAX
- GMAB
- Stock Information
- Founded
- BAX 1931
- GMAB 1999
- Country
- BAX United States
- GMAB Denmark
- Employees
- BAX N/A
- GMAB N/A
- Industry
- BAX Medical/Dental Instruments
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BAX Health Care
- GMAB Health Care
- Exchange
- BAX Nasdaq
- GMAB Nasdaq
- Market Cap
- BAX 17.3B
- GMAB 15.0B
- IPO Year
- BAX N/A
- GMAB N/A
- Fundamental
- Price
- BAX $31.92
- GMAB $20.59
- Analyst Decision
- BAX Hold
- GMAB Buy
- Analyst Count
- BAX 10
- GMAB 8
- Target Price
- BAX $41.40
- GMAB $43.00
- AVG Volume (30 Days)
- BAX 3.6M
- GMAB 1.5M
- Earning Date
- BAX 11-08-2024
- GMAB 11-06-2024
- Dividend Yield
- BAX 3.63%
- GMAB N/A
- EPS Growth
- BAX N/A
- GMAB 14.35
- EPS
- BAX 0.21
- GMAB 10.80
- Revenue
- BAX $15,062,000,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- BAX $3.81
- GMAB $30.31
- Revenue Next Year
- BAX $3.45
- GMAB $16.49
- P/E Ratio
- BAX $134.25
- GMAB $18.52
- Revenue Growth
- BAX 32.37
- GMAB 17.75
- 52 Week Low
- BAX $31.60
- GMAB $20.50
- 52 Week High
- BAX $44.01
- GMAB $32.89
- Technical
- Relative Strength Index (RSI)
- BAX 19.35
- GMAB 25.31
- Support Level
- BAX $31.61
- GMAB $21.90
- Resistance Level
- BAX $36.82
- GMAB $23.47
- Average True Range (ATR)
- BAX 0.82
- GMAB 0.45
- MACD
- BAX -0.41
- GMAB -0.12
- Stochastic Oscillator
- BAX 3.17
- GMAB 3.03
About BAX Baxter International Inc.
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.